z-logo
open-access-imgOpen Access
Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA
Author(s) -
Shengfang Ge,
Dan Wang,
Qing Kong,
Wei Gao,
Jiayi Sun
Publication year - 2017
Publication title -
oncology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.267
H-Index - 57
eISSN - 1555-3906
pISSN - 0965-0407
DOI - 10.3727/096504017x14878536973557
Subject(s) - transfection , cancer research , protein kinase b , pi3k/akt/mtor pathway , viability assay , flow cytometry , apoptosis , cell growth , breast cancer , cancer , tumor suppressor gene , biology , mtt assay , cell culture , medicine , microbiology and biotechnology , carcinogenesis , biochemistry , genetics
miR-152, as a tumor suppressor, has been reported to be downregulated in a number of cancer cell lines and tumor tissues, including breast cancer. This study aimed to investigate the role of miR-152 in human breast cancer and its underlying mechanisms. Human breast cancer cell line HCC1806 was transfected with hsa-miR-152-3p mimic, inhibitor, or scrambled negative controls. The efficiency of miR-152-3p transfection was evaluated by quantitative real-time PCR, and the effects on cell viability and apoptosis as well as on the PI3K/AKT signaling pathway were investigated by MTT assay, flow cytometry, and Western blot analysis, respectively. The binding effect of miR-152-3p on PIK3CA 3'-UTR was also investigated. The results suggested that miR-152-3p mimic transfection inhibited cell viability while inducing apoptosis of HCC1806 cells. Furthermore, miR-152-3p negatively regulated PIK3CA expression via binding to the 3'-UTR of PIK3CA and decreased the phosphorylation levels of AKT (Ser473) and RPS6 (Ser235/236) in HCC1806 cells. miR-152-3p inhibitor transfection showed the opposite effects. In conclusion, miR-152-3p might serve as a tumor suppressor in human breast cancer cells via negatively regulating PIK3CA expression to inhibit the activation of AKT and RPS6, leading to suppression of HCC1806 cell proliferation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here